StockData

BillionToOne vs Fulgent Genetics

BLLN and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BLLN and FLGT compare

BillionToOne is the larger company, worth 6.9 times as much as Fulgent Genetics ($4.6B against $666M).

BillionToOne grew revenue faster over the last twelve months (71.9% versus 6.8% for Fulgent Genetics).

BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −26.0% at Fulgent Genetics.

BillionToOne scores higher on the StockData Score (11 against 7 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBLLNFLGT
Size and price
Market cap$4.6B$666M
Share price$97.50$24.21
Change, 1 year8.3%−16.8%
Change, 5 years–−75.2%
Beta (5Y)0.380.49
Employees7131,300
StockData Score
Total score11 (better)7
Valuation score03 (better)
Growth score3 (better)0
Performance score2 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/S10.5×2.1× (better)
P/B8.1×0.7× (better)
EV/EBITDA77.8×–
P/FCF136×–
FCF yield0.74% (better)−15.6%
Fair value–$45.28
Margin of safety–46.5%
Growth
Revenue growth (TTM)71.9% (better)6.8%
Revenue growth, 5Y average–−5.2%
Profitability
Gross margin71.4% (better)35.6%
Operating margin10.2% (better)−37.7%
Net margin11.3% (better)−26.0%
FCF margin7.8% (better)−32.0%
Return on equity30.2% (better)−8.0%
Return on invested capital–−10.9%
Financial health
Debt / equity0.000.00 (better)
Interest coverage1655× (better)−1019.0×
Current ratio11.25 (better)6.34
Altman Z-score15.56 (better)5.25
Piotroski F-score8 (better)4
Dividends and buybacks
Buyback yield–9.6%
Shareholder yield0.00%9.6% (better)
Ownership
Held by institutions32.4%57.0%
Held by insiders55.7%39.5%
Insider net buying, 12 months−$58.5M−$286K (better)
Short interest, % of float14.2%12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.